Lack of BRAFV600E mutation in stage I and II of colorectal cancer

Mahsa Molaei; Roya Kishani Farahani; Mina Maftouh; Mohammad Yaghoob Taleghani; Mahsa Vahdatinia; Fatemeh Khatami; Ehsan Nazemalhosseini-Mojarad; Hamid Asadzadeh Aghdae; Akram Aboutorabi; Mohammad Reza Zali

Lack of BRAFV600E mutation in stage I and II of colorectal cancer

Gastroenterol Hepatol Bed Bench. 2016 Spring;9(2):94-9.

Affiliations

¹ Gastroenterology and Liver Disease Research center, Research Institute for Gastroenterology and liver Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
² Basic and molecular epidemiology of Gastrointestinal disorders Research center, Research Institute for Gastroenterology and liver disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
³ Student Research Committee, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

PMID: 27099668
PMCID: PMC4833847

Abstract

Aim: We aimed to explore the frequency of BRAFV600E mutation in Iranian patients with colorectal cancer (CRC) as well as its association with clinic pathological characteristic of patients.

Background: CRC is the third leading cause of cancer related death. There is a growing body of data showing the association of BRAFV600E mutation with malignant transformation and clinical outcome of different tumors, including CRC. These findings suggest that BRAFV600E mutation can be used as diagnostic and/or prognostic biomarker for management of cancer patients.

Patients and methods: A total of 85 patients with sporadic tumor were recruited. BRAFV600E mutation was investigated using sequencing of extracted DNAs from formalin-fixed paraffin-embedded (FFPE) tumor tissues. Electropherograms were analyzed using Laser-gene 6 software.

Results: More than 95% of patients were in stage I and II and none of them were in stage IV. Patients were mostly below 55 years old and tumors were dominantly located in the distal colon. Of note, no BRAFV600E mutations were detected in our population.

Conclusion: Our results showed no V600E mutation in the BRAF gene in stage I and II of CRC patients. Further studies in multi-center settings are warranted to examine the prognostic and/or predictive value of this marker in different stages of colorectal cancer patients.

Keywords: BRAFV600E mutation; CRC; DNA sequencing.